ArticlePloS one2018
Quercetin prevents rhinovirus-induced progression of lung disease in mice with COPD phenotype.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Quercetin on Inflammatory and Oxidative Stress Markers in COPD
Effects of Quercetin on the Oxidative Stress and Inflammatory Markers in COPD Phase II
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Analysis of the Clinical Efficacy and Molecular Mechanism of Xuefu Zhuyu Decoction in the Treatment of COPD Based on Meta-Analysis and Network Pharmacology.Computational and mathematical methods in medicine · 2022Pooled it
- Effectiveness of supplementation with quercetin-type flavonols for treatment of viral lower respiratory tract infections: Systematic review and meta-analysis of preclinical studies.Phytotherapy research : PTR · 2021Pooled it
- Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease.BMJ open respiratory research · 2020Trial
- Quercetin in COPD: A Multi-Target Approach to Modulate Inflammation, Oxidative Stress, and Epithelial Dysfunction.International journal of molecular sciences · 2026Review
- Quercetin-loaded silicon dioxide-graphene nanoparticles promotes M2 macrophage reprogramming in mycoplasma-induced pneumonia.Journal of inflammation (London, England) · 2026Article
- Research advances in polyphenols from Chinese herbal medicine for the prevention and treatment of chronic obstructive pulmonary disease: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Review
- Validation of a Traditional Medicine,Pharmaceuticals (Basel, Switzerland) · 2025Article
- Nutritional Support of Chronic Obstructive Pulmonary Disease.Nutrients · 2025Review
- Network Pharmacology and Experimental Validation of Jinwei Decoction for Enhancement of Glucocorticoid Anti-Inflammatory Effect in COPD through miR-155-5p.Combinatorial chemistry & high throughput screening · 2025Article
- Natural Products for the Management of Asthma and COPD.Handbook of experimental pharmacology · 2025Review
- Effect of oral treatment with quercetin on inflammatory and oxidative stress markers in patients with chronic obstructive pulmonary disease.Pharmacological research. Natural products · 2025Article
- Toxicological assessment ofFrontiers in toxicology · 2025Article
- Modulating mitochondria with natural extract compounds: from bench to clinical therapeutic opportunities for COPD.Frontiers in pharmacology · 2025Review
- Euphorbium compositum SN improves the innate defenses of the airway mucosal barrier network during rhinovirus infection.Respiratory research · 2024Article
- Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro.Inflammopharmacology · 2024Review
- Quercetin improves epithelial regeneration from airway basal cells of COPD patients.Respiratory research · 2024Article
- Quercetin alleviates PMPeerJ · 2024Article
- Screening COPD-Related Biomarkers and Traditional Chinese Medicine Prediction Based on Bioinformatics and Machine Learning.International journal of chronic obstructive pulmonary disease · 2024Article
- Investigation of the therapeutic effects and mechanisms of Houpo Mahuang Decoction on a mouse model of chronic obstructive pulmonary disease.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Acute exacerbations are the major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). Rhinovirus, which causes acute exacerbations may also accelerate progression of lung disease in these patients. Current therapies reduces the respiratory symptoms and does not treat the root cause of exacerbations effectively. We hypothesized that quercetin, a potent antioxidant and anti-inflammatory agent with antiviral properties may be useful in treating rhinovirus-induced changes in COPD. Mice with COPD phenotype maintained on control or quercetin diet and normal mice were infected with sham or rhinovirus, and after 14 days mice were examined for changes in lung mechanics and lung inflammation. Rhinovirus-infected normal mice showed no changes in lung mechanics or histology. In contrast, rhinovirus-infected mice with COPD phenotype showed reduction in elastic recoiling and increase in lung inflammation, goblet cell metaplasia, and airways cholinergic responsiveness compared to sham-infected mice. Interestingly, rhinovirus-infected mice with COPD phenotype also showed accumulation of neutrophils, CD11b+/CD11c+ macrophages and CD8+ T cells in the lungs. Quercetin supplementation attenuated rhinovirus-induced all the pathologic changes in mice with COPD phenotype. Together these results indicate that quercetin effectively mitigates rhinovirus-induced progression of lung disease in a mouse model of COPD. Therefore, quercetin may be beneficial in the treatment of rhinovirus-associated exacerbations and preventing progression of lung disease in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.